Trial reportThe Journal of allergy and clinical immunology2010
Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma.
Trial report in The Journal of allergy and clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01618929 (Phase 4 Study of Effects of Montelukast Treatment on Allergic Inflammation in Children With and Without Food Allergy, Single Centered, Randomised, Double Blind, Placebo Controlled Parallel Group Cross-over Study), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 4 Study of Effects of Montelukast Treatment on Allergic Inflammation in Children With and Without Food Allergy, Single Centered, Randomised, Double Blind, Placebo Controlled Parallel Group Cross-over Study
Who cites it
22 citing papers in PubMed, 64 citations in OpenAlex.
- Individualized therapy for persistent asthma in young children.The Journal of allergy and clinical immunology · 2016Trial
- Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma.The Journal of allergy and clinical immunology · 2014Trial
- Gene-by-environment effect of house dust mite on purinergic receptor P2Y12 (P2RY12) and lung function in children with asthma.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2012Trial
- Article
- P2Y6 signaling in alveolar macrophages prevents leukotriene-dependent type 2 allergic lung inflammation.The Journal of clinical investigation · 2019Article
- The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders.International journal of molecular sciences · 2019Review
- Montelukast Improves Symptoms and Lung Function in Asthmatic Women Compared With Men.Frontiers in pharmacology · 2019Article
- Biomarkers in asthma: state of the art.Asthma research and practice · 2018Review
- Chinese expert consensus on clinical use of non-invasive airway inflammation assessment in bronchial asthma.Journal of thoracic disease · 2015Review
- Chinese expert consensus on clinical use of non-invasive airway inflammation assessment in bronchial asthma.Annals of translational medicine · 2015Review
- Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.Immunology and allergy clinics of North America · 2015Review
- Role of biomarkers in understanding and treating children with asthma: towards personalized care.Pharmacogenomics and personalized medicine · 2013Review
- Stratified approaches to the treatment of asthma.British journal of clinical pharmacology · 2013Review
- Responsiveness to leukotriene D4 and methacholine for predicting efficacy of montelukast in asthma.Journal of thoracic disease · 2013Article
- Ratio of leukotriene e(4) to exhaled nitric oxide and the therapeutic response in children with exercise-induced bronchoconstriction.Allergy, asthma & immunology research · 2013Article
- An update on paediatric asthma.European respiratory review : an official journal of the European Respiratory Society · 2012Review
- Biomarkers in asthma: a real hope to better manage asthma.Clinics in chest medicine · 2012Review
- Severe asthma in childhood: recent advances in phenotyping and pathogenesis.Current opinion in allergy and clinical immunology · 2012Review
- Leukotrienes and airway inflammation.Biochimica et biophysica acta · 2011Review
- Is it time to revise the asthma guidelines?The Journal of allergy and clinical immunology · 2011Review
Corrections and comments
- Erratum issuedDosage error in article text
Authors and funding
10 authors at 8 institutions in 2 countries.
Funding
Abstract
backgroundA subset of children with asthma respond better to leukotriene receptor antagonists than to inhaled corticosteroids. Information is needed to identify children with these preferential responses.
objectiveWe sought to determine whether the ratio of urinary leukotriene E(4) (LTE(4)) to fractional exhaled nitric oxide (FE(NO)) delineates children with preferential responsiveness to montelukast compared with fluticasone propionate (FP) therapy.
methodsData from 318 children with mild-to-moderate asthma enrolled in 2 National Heart, Lung, and Blood Institute Childhood Asthma Research and Education Network studies (Characterizing the Response to a Leukotriene Receptor Antagonist and an Inhaled Corticosteroid [CLIC] and the Pediatric Asthma Controller Trial [PACT]) were analyzed. The association between LTE(4)/FE(NO) ratios at baseline and improved lung function or asthma control days (ACDs) with montelukast and FP therapy was determined, and phenotypic characteristics related to high ratios were assessed.
resultsLTE(4)/FE(NO) ratios were associated with a greater response to montelukast than FP therapy for FEV(1) measurements (2.1% increase per doubling of ratio, P = .001) and for ACDs per week (0.3-ACD increase, P = .009) in the CLIC study. In PACT the ratio was associated with greater ACD responsiveness to MT than FP therapy (0.6 ACD increase, P=.03) [corrected]. In a combined study analysis, LTE(4): FE(NO) ratios were associated with greater response to MT than FP therapy for FEV(1) (1.8% increase, P =.0005) and ACDs (0.4 increase, P =.001)[corrected].Children with LTE(4)/FE(NO) ratios at or above the 75th percentile were likely (P < .05) to be younger and female and exhibit lower levels of atopic markers and methacholine reactivity.
conclusionLTE(4)/FE(NO) ratios predict a better response to montelukast than FP therapy in children with mild-to-moderate asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.